Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)

Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms of action are currently unclear. This study aimed to: (i) reveal the metabolome of Mycobacterium smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Baptista, Rafael, Fazakerley, David M., Beckmann, Manfred, Baillie, Les, Mur, Luis A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865180/
https://www.ncbi.nlm.nih.gov/pubmed/29572459
http://dx.doi.org/10.1038/s41598-018-23110-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865180/
https://www.ncbi.nlm.nih.gov/pubmed/29572459
http://dx.doi.org/10.1038/s41598-018-23110-1

Ejemplares similares